Accuray Incorporated (ARAY) - Uzoq muddatli qarzning kapitalga nisbati
Accuray Incorporated (ARAY) uchun moliyaviy narx harakatlari robototexnika va murakkab uskunalar sertifikatsiyasi uchun patent himoyasi bilan pozitsiyasi mustahkamlangan kompaniyaning dinamikasini namoyish etadi. Ekologik profil elektronikaning xavfsiz qayta ishlanishiga asoslangan bo'lib, ushbu ko'rsatkich 4.13 darajasida turibdi. Biznes barqarorligi tajribali boshqaruv tomonidan ta'minlanadi, ular yangi tibbiy texnologiyalarni ishlab chiqish bilan bog'liq sezilarli xarajatlarga qaramay, sotuvlar geografiyasini samarali kengtirmoqda.
%20Uzoq%20muddatli%20qarzning%20o'z%20kapitaliga%20nisbati&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_ARAY_-_Accuray-Incorporated_-_Long-Term-Debt-to-Equity "accuray.com (ARAY): Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi 04.07.2022dan 29.10.2026gacha | 👁️GURU.Markets👁️")
Accuray Incorporated kompaniyasining tahliliy kesimlari
- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi ko'rsatkichlari:
- kompaniyaning balans qiymati tafsilotlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Qarzning kapitalga nisbati Accuray Incorporated|ARAY - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzdorlikning kapitalga nisbati accuray.com|ARAY - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Accuray|ARAY - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli majburiyatlari Accuray Incorporated
Kompaniyaning umumiy tahlili:Accuray Inc - ARAY
Accuray Incorporated (ARAY) investori uchun ushbu ko'rsatkich radiatsiya terapiyasi tizimlari bo'yicha global kengayish strategiyasini amalga oshirish davridagi moliyaviy barqarorlikning o'lchovi bo'lib xizmat qiladi. Uzoq muddatli majburiyatlarning kapitalga nisbatini tahlil qilish orqali siz bir yildan ortiq muddatga ega bo'lgan kreditlarning sof aktivlarga nisbatdagi ulushini baholaysiz, bu esa tajribali boshqaruv jamoasining qarz yukining kritik darajada ortishisiz kengayishni samarali moliyalashtirish qobiliyatini tasdiqlaydi.
Muhim raqobatchilar
Uzoq muddatli qarzning o'z kapitaliga nisbati BeiGene Ltd. (ONC)|Uzoq muddatli qarzning kapitalga nisbati HALO|Uzoq muddatli qarzning kapitalga nisbati Revolution Medicines Corp (RVMD)|Uzoq muddatli qarzning o'z kapitaliga nisbati Ascentage Pharma Group AAPG|CGON: Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|UroGen Pharma - Uzoq muddatli qarzning kapitalga nisbati|Bicara Therapeutics Inc (BCAX) - Uzoq muddatli qarzning o'z kapitaliga nisbati|PSNL: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Erasca Oncology (ERAS)|Uzoq muddatli qarzning o'z kapitaliga nisbati Delcath Systems, Inc.|YMAB: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning o'z kapitaliga nisbati AURA (Aura Biosciences)|CADL (candeltx.com) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati SLS (SELLAS Life Sciences Group)|ACTU - Uzoq muddatli qarzning o'z kapitaliga nisbati|CTOR: Uzoq muddatli qarzning o'z kapitaliga nisbati|HURA - Uzoq muddatli qarzning kapitalga nisbati|Protara Therapeutics, Inc. (TARA) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Fate Therapeutics Inc - Uzoq muddatli qarzning kapitalga koeffitsiyenti|WHWK (Aadi Bioscience, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati TScan TCRX|Uzoq muddatli qarzning kapitalga nisbati CSBR|Uzoq muddatli qarzning kapitalga nisbati xbiotech.com (XBIT)|Uzoq muddatli qarzning kapitalga nisbati CVM (CEL-SCI)|OSTX - Uzoq muddatli qarzning o'z kapitaliga nisbati|Radiopharm Theranostics Limited - Uzoq muddatli qarzning kapitalga nisbati|Artiva Biotherapeutics, Inc. (ARTV) - Uzoq muddatli qarzning o'z kapitaliga nisbati|ANL (adlainortye.com) - Uzoq muddatli qarzning o'z kapitaliga nisbati|verupharma.com (VERU) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Tempest Therapeutics, Inc.|XLO: Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati RENB|Uzoq muddatli qarzning kapitalga nisbati muraloncology.com (MURA)|Kairos Pharma - Uzoq muddatli qarzning o'z kapitaliga nisbati|OnKure Therapeutics, Inc. (OKUR) - Uzoq muddatli majburiyatlarning kapitalga nisbati|GDTC: Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti CRIS (Curis, Inc.)|APLM: Uzoq muddatli qarzning kapitalga nisbati|THAR - Uzoq muddatli qarzdorlikning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Advanced Biomed Inc.|Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi GNPX (genprex.com)|Uzoq muddatli qarzning kapitalga nisbati CLDI|Uzoq muddatli qarzning o'z kapitaliga nisbati Sunshine Biopharma Inc. SBFM|Uzoq muddatli qarzning o'z kapitaliga nisbati Xenetic Biosciences, Inc. XBIO|Salarius Pharma (SLRX) - Uzoq muddatli majburiyatlarning kapitalga nisbati|PPBT - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti AONC (American Oncology Network)|BeiGene (BGNE) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning o'z kapitaliga nisbati CKPT (Checkpoint Therapeutics Inc.)|Uzoq muddatli qarzning o'z kapitaliga nisbati Elevation Oncology, Inc.|Uzoq muddatli majburiyatlarning kapitalga nisbati iCAD Corp ICAD|Uzoq muddatli qarzning o'z kapitaliga nisbati Ikena Oncology, Inc. (IKNA)|NTBL (notablelabs.com) - Uzoq muddatli qarzning kapitalga koeffitsiyenti|Uzoq muddatli qarzning kapitalga nisbati VIRX (Viracta Therapeutics, Inc.)|Uzoq muddatli qarzning kapitalga nisbati MorphoSys Inc MOR|NAYA: Uzoq muddatli qarzning o'z kapitaliga nisbati|Ascentage - Uzoq muddatli kreditlarning kapitalga nisbati